Retrophin, Inc. (RTRX)
Stock Price:
$19.22 USD
0.11 (0.55%)
Updated Aug 7, 2020 1:39 PM EDT - Market open
Key Info
| Market Cap |
829.23M |
| Revenue (ttm) |
187.26M |
| Net Income (ttm) |
-92.01M |
| Shares Out |
50.91M |
| EPS (ttm) |
-2.12 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$19.22 |
| Previous Close |
$19.11 |
| Change ($) |
0.11 |
| Change (%) |
0.55% |
| Day's Open |
19.14 |
| Day's Range |
18.99 - 19.90 |
| Day's Volume |
91,338 |
| 52-Week Range |
8.98 - 21.92 |
More Stats
| Market Cap |
829.23M |
| Enterprise Value |
581.87M |
| Earnings Date (est) |
Oct 29, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
50.91M |
| Float |
43.29M |
| EPS (basic) |
-2.11 |
| EPS (diluted) |
-2.12 |
| FCF / Share |
-1.25 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
4.90M |
| Short Ratio |
8.23 |
| Short % of Float |
10.32% |
| Beta |
0.83 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
4.43 |
| PB Ratio |
3.09 |
| Revenue |
187.26M |
| Operating Income |
-74.89M |
| Net Income |
-92.01M |
| Free Cash Flow |
-56.10M |
| Net Cash |
247.37M |
| Net Cash / Share |
5.73 |
| Gross Margin |
90.84% |
| Operating Margin |
-39.99% |
| Profit Margin |
-49.10% |
| FCF Margin |
-29.96% |
| ROA |
-7.06% |
| ROE |
-30.89% |
| ROIC |
-19.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
7 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$29.43*
(53.16% upside)
Low
21.0
Current: $19.22
High
38.0
Target: 29.43
*Average 12-month price target from 7 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | 175 | 164 | 155 | 134 | 99.89 | 28.20 | - | - |
| Revenue Growth | 6.75% | 6.01% | 15.98% | 33.74% | 254.19% | - | - | - |
| Gross Profit | 170 | 159 | 151 | 129 | 97.71 | 27.63 | - | - |
| Operating Income | -107 | -68.45 | -34.40 | -39.83 | -36.97 | -79.81 | -24.77 | -30.26 |
| Net Income | -146 | -103 | -59.73 | -47.90 | 117 | -111 | -34.63 | -30.34 |
| Shares Outstanding | 42.34 | 40.43 | 38.77 | 37.00 | 33.56 | 25.06 | 14.21 | 3.66 |
| Earnings Per Share | -3.46 | -2.54 | -1.54 | -1.29 | 3.17 | -4.43 | -2.44 | -8.29 |
| Operating Cash Flow | -58.21 | -24.96 | 7.40 | -3.44 | -1.39 | -45.85 | -17.59 | -2.74 |
| Capital Expenditures | -0.20 | -0.73 | -0.89 | -1.43 | -0.02 | -0.66 | -0.12 | -0.02 |
| Free Cash Flow | -58.41 | -25.69 | 6.52 | -4.87 | -1.41 | -46.51 | -17.71 | -2.76 |
| Cash & Equivalents | 399 | 472 | 301 | 303 | 276 | 27.76 | 6.17 | 0.01 |
| Total Debt | 205 | 218 | 45.08 | 44.42 | 43.77 | 83.77 | 1.46 | 0.88 |
| Net Cash / Debt | 194 | 254 | 256 | 258 | 233 | -56.01 | 4.71 | -0.87 |
| Assets | 605 | 709 | 520 | 525 | 512 | 135 | 20.50 | 2.39 |
| Liabilities | 384 | 391 | 227 | 218 | 212 | 173 | 40.17 | 5.80 |
| Book Value | 221 | 318 | 293 | 308 | 300 | -37.25 | -19.67 | -3.41 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Retrophin, Inc. |
| Country |
United States |
| Employees |
221 |
| CEO |
Eric Dube |
Stock Information
| Ticker Symbol |
RTRX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: RTRX |
Description
Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences, NGLY1.org, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.